Get started
Author

Fernando Abdalla

Observed names: Abdalla, Fernando, F Abdalla, F. Abdalla, Fernando Abdalla Pereira
Institution: Weber
Observed institution: Weber
ORCID: 0000-0001-9549-5330
Observed ORCID: 0000-0001-9549-5330
OpenAlex ID: A5009958053
The economic burden of pulmonary arterial hypertension in Spain
2022 · Néboa Zozaya, Fernando Abdalla, et al. · BMC Pulmonary Medicine · 25
PDF
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
2022 · Néboa Zozaya, Fernando Abdalla, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 16
PDF
Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation
2022 · Néboa Zozaya, Renata Villoro, et al. · Acta Dermato Venereologica · 13
Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper
2023 · N. Zozaya, J. Villaseca, et al. · Orphanet Journal of Rare Diseases · 7
PDF
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain
2024 · Jorge Mestre-Ferrándiz, Agustín Rivero, et al. · BMC Infectious Diseases · 5
PDF
Evaluación y financiación de medicamentos innovadores en España: ¿dónde estamos y hacia dónde vamos?
2023 · Néboa Zozaya, Javier Villaseca, et al. · Economía de la Salud · 2
PDF
POSA103 Estimation of the Economic and Social Burden of Pulmonary Arterial Hypertension in Spain
2022 · N Zozaya, F Abdalla, et al. · Value in Health · 2
Inflation, competitive dynamics, and economic sustainability in the Spanish pharmaceutical sector
2026 · Fernando Abdalla Pereira, Javier Villaseca, et al. · Journal of Pharmaceutical Health Services Research
El valor social de la red de farmacias
2026 · Javier Villaseca Carmena, Fernando Abdalla, et al.
PDF
Libro blanco del hipoparatiroidismo crónico en España
2026 · Fernando Abdalla, Ignacio Juan Bernabeu, et al.
HTA3 The Clinical and Economic Value of a Sustained Response in the Treatment of Moderate-to-Severe Psoriasis in Spain: The PSOVALUE Project
2022 · A Hidalgo Vega, N Zozaya, et al. · Value in Health
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
2022 · Zozaya, Néboa, Abdalla, Fernando, et al. · Figshare
Works count: 24
Citation count: 70
H-index: 5
I10-index: 3
Year
Topic
Type